Design, Synthesis, and Biological Activity Study of 6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinoline Derivatives Against Multidrug Resistance in Eca109/Vcr Cells DOI
Qin Ouyang, Bo Xu, Tao Yu

et al.

Published: Jan. 1, 2025

Language: Английский

P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators DOI

Yang Guo,

Milad Ashrafizadeh, Murtaza M. Tambuwala

et al.

Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(11), P. 104161 - 104161

Published: Sept. 7, 2024

Language: Английский

Citations

22

Advances in cuproptosis harnessing copper-based nanomaterials for cancer therapy DOI
Yuanying Yang, Chen Dong, Xuehua Ma

et al.

Journal of Materials Chemistry B, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

This review discusses the recent developments in copper-based nanomaterials that utilize copper-induced cell death, categorized by materials systems, while highlighting limitations of current cuproptosis related nanomaterials.

Language: Английский

Citations

2

Exploring extracellular RNA as drivers of chemotherapy resistance in cancer DOI

Yumna Khan,

Md Sadique Hussain, Prasanna Srinivasan Ramalingam

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: Jan. 21, 2025

Language: Английский

Citations

2

Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy DOI Creative Commons
Lihua Xu,

Mingzheng Peng,

Tingting Gao

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 11(7)

Published: Dec. 8, 2023

Abstract Endogenous essential metal ions play an important role in many life processes, especially tumor development and immune response. The approval of various metallodrugs for therapy brings more attention to the antitumor effect ions. With deepening understanding regulation mechanisms ion homeostasis vivo, breaking intracellular becomes a new means inhibit proliferation cells activate Diverse nanomedicines with loading small molecular regulators or have been developed disrupt cells, higher safety efficiency than free compounds. This comprehensive review focuses on latest progress regulation‐based including calcium (Ca 2+ ), ferrous (Fe cuprous (Cu + managanese (Mn zinc (Zn ). physiological functions processes are summarized guide design nanomedicines. Then ions‐based some efficient synergistic therapies highlighted. Finally, challenges future developments also discussed, hoping provide reference finding effective therapies.

Language: Английский

Citations

37

Natural products reverse cancer multidrug resistance DOI Creative Commons
Jiayu Zou, Qilei Chen,

Xiao-Ci Luo

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: March 8, 2024

Cancer stands as a prominent global cause of death. One the key reasons why clinical tumor chemotherapy fails is multidrug resistance (MDR). In recent decades, accumulated studies have shown how Natural Product-Derived Compounds can reverse MDR. Discovering novel potential modulators to reduce MDR by has become popular research area across globe. Numerous mainly focus on natural products including flavonoids, alkaloids, terpenoids, polyphenols and coumarins for their modulatory activity. regulating signaling pathways or relevant expressed protein gene. Here we perform deep review previous achievements, advances in development treatment This aims provide some insights study products.

Language: Английский

Citations

14

ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation DOI

Furong Ma,

Yulong Li,

Mao-Hua Cai

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 270, P. 116387 - 116387

Published: April 1, 2024

Language: Английский

Citations

10

Spiroindoline quinazolinedione derivatives as inhibitors of P-glycoprotein: potential agents for overcoming multidrug resistance in cancer therapy DOI
Fatemeh Moosavi,

Masoumeh Divar,

Soghra Khabnadideh

et al.

Molecular Diversity, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Language: Английский

Citations

1

Small molecule inhibitors targeting heat shock protein 90: An updated review DOI
Yulong Li, Jinyun Dong, Jiang‐Jiang Qin

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 275, P. 116562 - 116562

Published: June 4, 2024

Language: Английский

Citations

8

Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor DOI Creative Commons
Sifeng Zhu, Chao Sun,

Zimin Cai

et al.

Materials Today Bio, Journal Year: 2024, Volume and Issue: 26, P. 101029 - 101029

Published: March 19, 2024

Multi-drug resistance (MDR) in advanced breast cancer (ABC) is triggered by the high expression of P-glycoprotein (P-gp), which reduces intracellular concentration anti-tumor drugs, turn preventing oxidative stress damage to cytoplasmic and mitochondrial membranes. It therefore clinical relevance develop P-gp-specific targeted nanocarriers for treatment drug resistant ABC. Herein, a carrier targeting CD44 mitochondria was synthesised delivery encequidar (ER, P-gp inhibitor) paclitaxel (PTX). HT@ER/PTX nanoparticles (ER:PTX molar ratio 1:1) had excellent inhibition ability induce apoptosis MCF-7/PTX cells vitro. Furthermore, showed more efficacy than PTX (Taxol®) xenograft mouse model cells; tumor inhibitory rates Taxol® were 72.64% ± 4.41% 32.36% 4.09%, respectively. The survival tumor-bearing mice administered prolonged compared that treated with Taxol®. In addition, not only inhibited P-gp-mediated removal toxic lipid peroxidation byproducts resulting from drugs but also upregulated dynamics-related protein, fostering damage, induced activation Caspase-3 pathway. Our findings indicate co-delivery inhibitors could be practical approach treating multi-drug

Language: Английский

Citations

7

Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition DOI Creative Commons

Hyeonji Yoo,

Yeonjin Kim, Jinseong Kim

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(17), P. 3994 - 3994

Published: Aug. 23, 2024

Drug resistance remains a critical barrier in cancer therapy, diminishing the effectiveness of chemotherapeutic, targeted, and immunotherapeutic agents. Overexpression proteins such as B-cell lymphoma 2 (Bcl-2), inhibitor apoptosis (IAPs), protein kinase B (Akt), P-glycoprotein (P-gp) various cancers leads to by inhibiting apoptosis, enhancing cell survival, expelling drugs. Although several inhibitors targeting these have been developed, their clinical use is often hampered systemic toxicity, poor bioavailability, development. Nanoparticle-based drug delivery systems present promising solution improving solubility, stability, targeted delivery. These leverage Enhanced Permeation Retention (EPR) effect accumulate tumor tissues, reducing off-target toxicity increasing therapeutic efficacy. Co-encapsulation strategies involving anticancer drugs within nanoparticles shown potential achieving coordinated pharmacokinetic pharmacodynamic profiles. This review discusses mechanisms resistance, limitations current inhibitors, advantages nanoparticle overcoming challenges. By advancing technologies, we can enhance treatment outcomes move towards more effective therapies.

Language: Английский

Citations

7